FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ADULTS1
SKYRIZI VS COSENTYX® (secukinumab)2*
SKYRIZI VS STELARA® (ustekinumab)1,4†
SKYRIZI VS HUMIRA® (adalimumab)5
DISCOVER HOW SKYRIZI PERFORMED VS 3 AGENTS
In different biologic classes
*SOURCING: In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab are not publicly available.3
†ACTIVE COMPARATOR: The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.